Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 25 | 2023 | 417 | 5.260 |
Why?
|
| Mastectomy | 15 | 2023 | 38 | 3.410 |
Why?
|
| Surgeons | 8 | 2023 | 89 | 2.680 |
Why?
|
| Organ Sparing Treatments | 2 | 2020 | 11 | 1.350 |
Why?
|
| Mastectomy, Segmental | 8 | 2023 | 31 | 1.300 |
Why?
|
| Nipples | 4 | 2021 | 5 | 1.240 |
Why?
|
| Ergonomics | 3 | 2021 | 6 | 1.050 |
Why?
|
| Mammaplasty | 3 | 2023 | 7 | 0.990 |
Why?
|
| Mastectomy, Subcutaneous | 1 | 2021 | 1 | 0.770 |
Why?
|
| Mammography | 1 | 2019 | 48 | 0.640 |
Why?
|
| Phyllodes Tumor | 1 | 2017 | 2 | 0.590 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 121 | 0.590 |
Why?
|
| Rare Diseases | 1 | 2017 | 13 | 0.590 |
Why?
|
| Female | 25 | 2023 | 15583 | 0.550 |
Why?
|
| Quality of Life | 2 | 2019 | 656 | 0.460 |
Why?
|
| Humans | 27 | 2023 | 28117 | 0.450 |
Why?
|
| Surgical Oncology | 2 | 2019 | 6 | 0.320 |
Why?
|
| Middle Aged | 13 | 2023 | 9188 | 0.300 |
Why?
|
| Pilot Projects | 2 | 2019 | 435 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 316 | 0.270 |
Why?
|
| Prospective Studies | 3 | 2021 | 1763 | 0.270 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 372 | 0.240 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2022 | 34 | 0.240 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2019 | 21 | 0.240 |
Why?
|
| Prognosis | 4 | 2019 | 819 | 0.230 |
Why?
|
| Receptors, Estrogen | 2 | 2022 | 61 | 0.210 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2022 | 13 | 0.210 |
Why?
|
| Breast Implants | 2 | 2019 | 10 | 0.200 |
Why?
|
| Breast Neoplasms, Male | 1 | 2022 | 10 | 0.200 |
Why?
|
| Operating Rooms | 1 | 2021 | 14 | 0.190 |
Why?
|
| Workload | 1 | 2021 | 33 | 0.190 |
Why?
|
| Oncologists | 1 | 2021 | 2 | 0.180 |
Why?
|
| Societies, Medical | 2 | 2019 | 153 | 0.180 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 34 | 0.180 |
Why?
|
| Adult | 8 | 2023 | 8036 | 0.180 |
Why?
|
| Burnout, Professional | 1 | 2021 | 41 | 0.170 |
Why?
|
| Contraindications, Procedure | 1 | 2020 | 4 | 0.170 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 1811 | 0.170 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 25 | 0.170 |
Why?
|
| Medical Overuse | 1 | 2019 | 8 | 0.170 |
Why?
|
| Acellular Dermis | 1 | 2019 | 7 | 0.160 |
Why?
|
| Breast Implantation | 1 | 2019 | 5 | 0.160 |
Why?
|
| Radiologists | 1 | 2019 | 7 | 0.160 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 51 | 0.160 |
Why?
|
| Receptor, ErbB-2 | 1 | 2019 | 50 | 0.160 |
Why?
|
| Margins of Excision | 1 | 2019 | 31 | 0.160 |
Why?
|
| Radiation Oncology | 1 | 2019 | 14 | 0.160 |
Why?
|
| Intraoperative Care | 1 | 2019 | 43 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 66 | 0.160 |
Why?
|
| Operative Time | 1 | 2019 | 93 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 132 | 0.160 |
Why?
|
| Stromal Cells | 1 | 2018 | 32 | 0.150 |
Why?
|
| Hemangiosarcoma | 1 | 2017 | 9 | 0.150 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 229 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 244 | 0.140 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 202 | 0.140 |
Why?
|
| Decision Making | 1 | 2019 | 229 | 0.140 |
Why?
|
| Sleep Wake Disorders | 1 | 2017 | 120 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 32 | 0.130 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 87 | 0.130 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2015 | 42 | 0.120 |
Why?
|
| Colonic Neoplasms | 1 | 2015 | 61 | 0.120 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 53 | 0.120 |
Why?
|
| Neoplasms | 1 | 2017 | 236 | 0.120 |
Why?
|
| Aged | 8 | 2023 | 9223 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 145 | 0.120 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2017 | 227 | 0.120 |
Why?
|
| Pain | 1 | 2017 | 396 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 177 | 0.110 |
Why?
|
| Retrospective Studies | 6 | 2019 | 3537 | 0.110 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 1201 | 0.100 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 929 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 555 | 0.090 |
Why?
|
| Young Adult | 3 | 2023 | 2048 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2016 | 930 | 0.080 |
Why?
|
| Rosaniline Dyes | 1 | 2008 | 2 | 0.080 |
Why?
|
| Radioisotopes | 1 | 2008 | 13 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 89 | 0.080 |
Why?
|
| Adolescent | 2 | 2023 | 2291 | 0.070 |
Why?
|
| Time Factors | 2 | 2019 | 1489 | 0.060 |
Why?
|
| United States | 2 | 2021 | 2161 | 0.050 |
Why?
|
| Self Concept | 1 | 2023 | 42 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2023 | 58 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 35 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2019 | 665 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2023 | 157 | 0.050 |
Why?
|
| Emotions | 1 | 2021 | 87 | 0.050 |
Why?
|
| Video Recording | 1 | 2019 | 35 | 0.040 |
Why?
|
| Anxiety | 1 | 2021 | 156 | 0.040 |
Why?
|
| Fear | 1 | 2019 | 48 | 0.040 |
Why?
|
| Male | 3 | 2022 | 15173 | 0.040 |
Why?
|
| Body Image | 1 | 2019 | 27 | 0.040 |
Why?
|
| Esthetics | 1 | 2019 | 12 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2019 | 1890 | 0.040 |
Why?
|
| Carcinoma, Lobular | 1 | 2019 | 21 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 81 | 0.040 |
Why?
|
| Patient Preference | 1 | 2019 | 33 | 0.040 |
Why?
|
| Pectoralis Muscles | 1 | 2019 | 18 | 0.040 |
Why?
|
| Patient Participation | 1 | 2019 | 53 | 0.040 |
Why?
|
| Surgical Flaps | 1 | 2019 | 51 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2019 | 91 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 141 | 0.040 |
Why?
|
| Consensus | 1 | 2019 | 97 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2019 | 135 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2018 | 66 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 206 | 0.040 |
Why?
|
| Wound Healing | 1 | 2019 | 158 | 0.040 |
Why?
|
| Sleep | 1 | 2021 | 338 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 4846 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 354 | 0.040 |
Why?
|
| Needles | 1 | 2016 | 20 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 311 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 475 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2018 | 242 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 449 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1368 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2019 | 538 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 790 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 306 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 375 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 1181 | 0.030 |
Why?
|
| Drug Hypersensitivity | 1 | 2008 | 6 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2008 | 14 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 145 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 275 | 0.020 |
Why?
|
| Linear Models | 1 | 2008 | 255 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 3531 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 511 | 0.020 |
Why?
|